Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL691939 | 0.88 | SLC22A16 (0.42) | SLC22A16SMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL4999236 | 0.84 | CHRM2 (0.35) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Glycerin SCHEMBL5667635 | 0.82 | SMN1; SMN2 (0.36) | SLC22A16SMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL14742785 | 0.78 | BBOX1 (0.41) | SLC22A16TSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL8010 | 0.78 | BBOX1 (0.41) | SLC22A16TSHRCHRM2CHRM4CHRM1 | |
| Glycerin SCHEMBL28327360 | 0.77 | TSHR (0.44) | SLC22A16TSHRCHRM2CHRM4CHRM1 | |
| Water SCHEMBL17373732 | 0.76 | BBOX1 (0.39) | SLC22A16TSHRCHRM2CHRM4CHRM1 | |
| Bromide SCHEMBL8416789 | 0.76 | BBOX1 (0.39) | SLC22A16TSHRCHRM2CHRM4CHRM1 | |
| Hydrochloric Acid SCHEMBL434365 | 0.76 | MAPT (0.43) | SLC22A16TSHRCHRM2CHRM4CHRM1 | |
| Glycerin SCHEMBL7038290 | 0.76 | ALDH1A1 (0.56) | TSHRSMN1; SMN2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381377-B1 | A COMPOSITION INCLUDING A GINKGOLIDE AND APOCYNIN WHICH INTERFERES WITH THE ARACHIDONIC ACID CASCADE | AKL TECHNOLOGIES LTD (GB) | 2012-01-11 | — | — | EP | disclosed |
| US-20110086119-A1 | Preparation for the relief of disease | AKL TECHNOLOGIES LIMITED | 2011-04-14 | — | — | US | disclosed |
| US-7067158-B2 | Preparation for the relief of disease | AKL TECHNOLOGIES LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-20060127508-A1 | Preparation for the relief of disease | AKL TECHNOLOGIES LIMITED | 2006-06-15 | — | — | US | disclosed |
| US-20040022879-A1 | Preparation for the relief of disease | AKL RESEARCH AND DEVELOPMENT LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1381377-A2 | A COMPOSITION INCLUDING A PLATELET ACTIVATING FACTOR INHIBITOR AND AN ANTIOXIDANT WHICH INTERFERES WITH THE ARACHIDONIC ACID CASCADE | AKL Technologies Limited (GB) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002032435-A9 | A COMPOSITION INCLUDING A PLATELET ACTIVATING FACTOR INHIBITOR AND AN ANTIOXIDANT WHICH INTERFERES WITH THE ARACHIDONIC ACID CASCADE | AKL TECHNOLOGIES LTD (GB) | 2003-12-18 | — | — | WO | disclosed |
| WO-2002032435-A2 | A COMPOSITION INCLUDING A PLATELET ACTIVATING FACTOR INHIBITOR AND AN ANTIOXIDANT WHICH INTERFERES WITH THE ARACHIDONIC ACID CASCADE | AKL TECHNOLOGIES LIMITED (GB) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040022879-A1 | Preparation for the relief of disease | F2, PLA2G7, ALOX15B | SLC22A16 4583/4885TSHR 2810/4885CHRM2 3724/4885 |
| US-20060127508-A1 | Preparation for the relief of disease | F2, PLA2G7, ALOX15B | SLC22A16 4605/4885TSHR 2739/4885CHRM2 3809/4885 |
| US-20110086119-A1 | Preparation for the relief of disease | F2, PLA2G7, ALOX15B | SLC22A16 4605/4885TSHR 2739/4885CHRM2 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.